MBNL1 identified as a potential cancer drug target for a type of childhood leukemia
Scientists from St. Jude Children's Research Hospital and collaborators have discovered that the RNA-binding protein MBNL1 promotes the growth of a form of childhood leukemia characterized by KMT2A gene rearrangements. The finding identifies MBNL1 as a promising therapeutic target for future drug development. The results were published August 7 in Science Advances.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
